Arch Biopartners Announces Start of Phase I Human Trial for Metablok

TORONTO, Canada I June 19, 2019 I Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has initiated the Phase I human trial for Metablok (“LSALT peptide”), the Company’s lead drug candidate for treating acute kidney injury and other organ damage caused by inflammation.

Recruiting of participants has already begun with dosing of the first volunteer expected by the end of the month. A total of forty-four participants are scheduled to be enrolled in the trial over the next few months.

The Phase I trial, being conducted at the Alfred Hospital in Melbourne, Australia, is a double-blind, placebo-controlled, randomized, single and multiple ascending dose study to evaluate the safety and pharmacokinetic profile of Metablok in healthy participants.

Other Corporate Developments

The Company also announced today that a shareholder of the Company exercised 50,000 warrants expiring in July, 2019 to buy 50,000 common shares of the Company for proceeds of $25,000.

About Arch Biopartners

Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact.  Arch has established a diverse portfolio that includes Metablok, a potential treatment for inflammation, sepsis and cancer metastasis; AB569, a potential new treatment for antibiotic resistant bacterial infections in the lung, urinary tract or wounds; and, ‘Borg’ peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.

For more information on Arch Biopartners, its technologies and other public documents Arch has filed on SEDAR, please visit www.archbiopartners.com

SOURCE: Arch Biopartners

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top